Analog Devices Inc
Change company Symbol lookup
Select an option...
ADI Analog Devices Inc
BAC Bank of America Corp
CLOV Clover Health Investments Corp
HRL Hormel Foods Corp
DD Dupont De Nemours Inc
PSRU Valiant Eagle Inc
CRM Salesforce.Com Inc
VLYPP Valley National Bancorp
FEMKX Fidelity® Emerging Markets Fund
XPEV Xpeng Inc
Go

Information Technology : Semiconductors & Semiconductor Equipment | Large Cap Blend
Company profile

Analog Devices, Inc. (Analog Devices) designs, manufactures and markets a portfolio of solutions that leverage high-performance analog, mixed-signal and digital signal processing technology, including integrated circuits (ICs), algorithms, software and subsystems. Its products include Analog Products, Converters, Amplifiers/Radio Frequency, Other Analog, Power Management and Reference, and Digital Signal Processing Products. The Company is a supplier of data converter products. The Company is a supplier of high-performance amplifiers. Its analog product line also includes products of high performance radio frequency (RF) ICs. The Company's DSPs are used for high-speed numeric calculations. The Company offers its products for applications in various end markets, such as industrial, automotive, consumer and communications. The Company operates in the United States, Rest of North/South America, Europe, Japan and China.

Postmarket

Last Trade
Delayed
$156.38
2.09 (1.35%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$154.29
Day's Change
-4.30 (-2.71%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
159.41
Day's Low
154.03
Volume
(Below Average)
Volume:
3,016,479

10-day average volume:
3,526,468
3,016,479

EOLS Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Evolus, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: December 15, 2020

10:02 am ET December 15, 2020 (Newsfile) Print

New York, New York--(Newsfile Corp. - December 15, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Evolus, Inc. (NASDAQ: EOLS) ("Evolus" or "the Company") and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Evolus securities between February 1, 2019 to July 6, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/eols.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements that: (1) the real source of botulinum toxin bacterial strain as well as the manufacturing processes used to develop JeuveauT originated with and were misappropriated from Medytox; (2) sufficient evidentiary support existed for the allegations that Evolus misappropriated certain trade secrets relating to the botulin toxin strain and the manufacturing processes for the development of JeuveauT; (3) as a result, Evolus faced a real threat of regulatory and/or court action, prohibiting the import, marketing, and sale of JeuveauT; (4) which in turn seriously threatened Evolus' ability to commercialize JeuveauT in the United States and generate revenue; and (5) any revenues generated from the sale of JeuveauT were based on Evolus' unlawful activities, including the misappropriation of trade secrets and secret manufacturing processes belonging to Allergan and Medytox.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/eols or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Evolus you have until December 15, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/69541

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.